| APELLIS PHARMACEUTICALS |
| USA |
| Gesundheit |
| US03753U1060 / A2JAAW |
| 1JK (Frankfurt) / APLS (NASDAQ) |
| FRA:1JK, ETR:1JK, 1JK:GR, NASDAQ:APLS |
| - |
| https://www.apellis.com/ |
|
Apellis Pharmaceuticals Inc. is a biopharmaceutica..
>Volltext.. |
| 2520.65 Mio. EUR |
| 2516.19 Mio. EUR |
| 872.79 Mio. EUR |
| 70.49 Mio. EUR |
| 38.63 Mio. EUR |
| 0.3 EUR |
| 408.21 Mio. EUR |
| 412.7 Mio. EUR |
| 67.72 Mio. EUR |
| 1.72 |
| 34.84% |
| - |
| - |
| - |
| - |
| APELLIS |
| 16.01.26 |
|
||||
|